View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Amgen Inc.: Key facts and statistics - LTM June 2024

A summary company profile, detailing Amgen’s business operations and financial highlights.

Amgen Inc. - June 2024 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Amgen Inc.: Update following outlook revision to stable from negative

Our credit view of this issuer reflects its high profit margins and strong cash flow, constrained by its unresolved IRS tax disputes.

Moody's Ratings affirms Amgen's Baa1 ratings; revises outlook to stabl...

Moody's Ratings (Moody's) affirmed the ratings of Amgen Inc. (Amgen) including the Baa1 senior unsecured notes rating, (P)Baa1 senior unsecured shelf rating, (P)Baa1 senior unsecured medium term note program rating, and Prime-2 commercial paper rating. At the same time, we revised Amgen's outlook to...

Amgen Inc. - March 2024 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Amgen Inc. - December 2023 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Amgen Inc.: Near-term focus on pipeline execution, integration of Hori...

Our credit view of this issuer reflects its high profit margins and strong cash flow, constrained by unresolved IRS tax disputes

Moody's announces completion of a periodic review of ratings of Amgen ...

Moody's Ratings has completed a periodic review of the ratings of Amgen Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 7 March 2024 in which Moody's reassessed the appropriateness of the ratings in the context of the relevant...

Amgen Inc. - September 2023 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

 PRESS RELEASE

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

The Vanguard Group, Inc. (IRSH) Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc 06-Oct-2023 / 13:34 GMT/BST Ap27   FORM 8.3   IRISH TAKEOVER PANEL   OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE   1. KEY INFORMATION           Full name of discloser The Vanguard Group, Inc.         Owner or controller of interests and short positions disclosed, if different from 1(a) The naming of nom...

 PRESS RELEASE

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

The Vanguard Group, Inc. (IRSH) Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc 05-Oct-2023 / 13:44 GMT/BST Ap27   FORM 8.3   IRISH TAKEOVER PANEL   OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE   1. KEY INFORMATION           Full name of discloser The Vanguard Group, Inc.         Owner or controller of interests and short positions disclosed, if different from 1(a) The naming of nom...

 PRESS RELEASE

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

The Vanguard Group, Inc. (IRSH) Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc 04-Oct-2023 / 13:46 GMT/BST Ap27   FORM 8.3   IRISH TAKEOVER PANEL   OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE   1. KEY INFORMATION           Full name of discloser The Vanguard Group, Inc.         Owner or controller of interests and short positions disclosed, if different from 1(a) The naming of nom...

 PRESS RELEASE

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

The Vanguard Group, Inc. (IRSH) Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc 03-Oct-2023 / 13:28 GMT/BST Ap27   FORM 8.3   IRISH TAKEOVER PANEL   OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE   1. KEY INFORMATION           Full name of discloser The Vanguard Group, Inc.         Owner or controller of interests and short positions disclosed, if different from 1(a) The naming of nom...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: October 2, 2023

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

The Vanguard Group, Inc. (IRSH) Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc 02-Oct-2023 / 14:07 GMT/BST Ap27   FORM 8.3   IRISH TAKEOVER PANEL   OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE   1. KEY INFORMATION           Full name of discloser The Vanguard Group, Inc.         Owner or controller of interests and short positions disclosed, if different from 1(a) The naming of nom...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: September 30, 2023

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

The Vanguard Group, Inc. (IRSH) Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc 29-Sep-2023 / 13:48 GMT/BST Ap27   FORM 8.3   IRISH TAKEOVER PANEL   OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE   1. KEY INFORMATION           Full name of discloser The Vanguard Group, Inc.         Owner or controller of interests and short positions disclosed, if different from 1(a) The naming of nom...

 PRESS RELEASE

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

The Vanguard Group, Inc. (IRSH) Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc 28-Sep-2023 / 12:51 GMT/BST Ap27   FORM 8.3   IRISH TAKEOVER PANEL   OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE   1. KEY INFORMATION           Full name of discloser The Vanguard Group, Inc.         Owner or controller of interests and short positions disclosed, if different from 1(a) The naming of nom...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: September 27, 2023

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

The Vanguard Group, Inc. (IRSH) Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc 27-Sep-2023 / 12:49 GMT/BST Ap27   FORM 8.3   IRISH TAKEOVER PANEL   OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE   1. KEY INFORMATION           Full name of discloser The Vanguard Group, Inc.         Owner or controller of interests and short positions disclosed, if different from 1(a) The naming of nom...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch